| 9.61 0.16 (1.69%) | 12-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.56  |
1-year : | 13.5 |
| Resists | First : | 9.89 |
Second : | 11.56 |
| Pivot price | 8.2 |
|||
| Supports | First : | 7.87 |
Second : | 6.63 |
| MAs | MA(5) : | 9.4 |
MA(20) : | 7.94 |
| MA(100) : | 7.83  |
MA(250) : | 7.92 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 90.4 |
D(3) : | 90 |
| RSI | RSI(14): 73.7 |
|||
| 52-week | High : | 11.25 | Low : | 5.86 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ INMB ] has closed below upper band by 16.7%. Bollinger Bands are 167.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.91 - 9.95 | 9.95 - 9.99 |
| Low: | 9.04 - 9.08 | 9.08 - 9.12 |
| Close: | 9.54 - 9.6 | 9.6 - 9.67 |
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Wed, 29 Nov 2023
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of ... - Yahoo Finance
Mon, 27 Nov 2023
INmune Bio Receives EMA's Authorization in France and Spain for ... - Yahoo Finance
Fri, 17 Nov 2023
Biotech Stocks: The Race For An Alzheimer's Cure Takes Off - Investor's Business Daily
Wed, 15 Nov 2023
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for ... - BioSpace
Sun, 05 Nov 2023
7 Earnings Losers to Load Up On Right Now - InvestorPlace
Thu, 02 Nov 2023
INmune Bio, Inc. (NASDAQ:INMB) Q3 2023 Earnings Call Transcript - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 1.173e+007 (%) |
| Held by Institutions | 35 (%) |
| Shares Short | 1,270 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -19 % |
| Return on Assets (ttm) | 832.5 % |
| Return on Equity (ttm) | -23 % |
| Qtrly Rev. Growth | 224000 % |
| Gross Profit (p.s.) | -28.63 |
| Sales Per Share | -25.82 |
| EBITDA (p.s.) | 190816 |
| Qtrly Earnings Growth | -1.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.38 |
| Price to Cash Flow | 7.71 |
| Dividend | 0 |
| Forward Dividend | 1.22e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|